If you manufacture, distribute, or submit premarket notifications for non-invasive bone growth stimulators, the regulatory landscape just shifted under your feet — in a meaningful, generally positive way. The FDA issued a final order in April 2026 reclassifying these devices from Class III (premarket approval required) down to Class II (premarket notification, or 510(k)), subject to newly established special controls.
This is not a minor administrative update. It changes the pathway, the cost structure, and the evidentiary burden for bringing these devices to market. And it comes with compliance obligations that deserve your attention now.
What the FDA Actually Did
Published in the Federal Register on April 16, 2026 (Docket No. FDA-2026-07366), FDA's final order reclassifies non-invasive bone growth stimulators — product codes LOF and LPQ — from postamendments Class III devices into Class II, with premarket notification (510(k)) as the required pathway.
Alongside the reclassification, FDA codified a new device classification regulation titled "non-invasive bone growth stimulator" and established the special controls that manufacturers must meet to demonstrate reasonable assurance of safety and effectiveness. Those special controls carry real weight — they are not optional guidance; they are the conditions under which Class II status holds.
In my view, this reclassification reflects a reasonable FDA determination that the existing body of clinical evidence, combined with a well-defined set of special controls, can adequately manage the risks these devices present. That is how reclassification is supposed to work.
Why This Matters: The Class III to Class II Shift
The difference between Class III and Class II is not just a label. It is a fundamentally different regulatory burden.
| Feature | Class III (Pre-Reclassification) | Class II (Post-Reclassification) |
|---|---|---|
| Premarket Pathway | Premarket Approval (PMA) | Premarket Notification (510(k)) |
| Evidence Standard | Valid scientific evidence of safety & effectiveness | Substantial equivalence to predicate |
| Average Review Time | 180+ days (often longer) | ~90–100 days median |
| Typical Cost | $500,000–$1M+ | $50,000–$200,000 |
| Post-Approval Studies | Often required as PMA conditions | Generally not required |
| Special Controls | Not applicable | Required — newly established |
Under Class III, a manufacturer needed a full PMA — a resource-intensive process that smaller manufacturers and new market entrants found prohibitive. Under Class II, the 510(k) pathway requires demonstrating substantial equivalence to a legally marketed predicate device, while also complying with the newly established special controls. That is a significantly more accessible path.
According to FDA data, the average PMA requires approximately 1,200 hours of FDA review time compared to roughly 200 hours for a 510(k). That difference in regulatory burden has real market consequences.
What Are the Special Controls?
This is the piece most summaries gloss over, and it is the piece that will determine whether your device actually sails through a 510(k) or hits headwinds.
Special controls are device-specific requirements that, together with general controls, provide reasonable assurance of safety and effectiveness when PMA-level evidence is not required. For non-invasive bone growth stimulators, the FDA's newly codified special controls address the specific risks these devices present — electromagnetic output, clinical claims, labeling, and performance testing.
In practical terms, manufacturers should expect the special controls to require:
- Performance testing demonstrating that the device delivers the intended electromagnetic or acoustic stimulus within defined parameters
- Biocompatibility evaluation per FDA-recognized consensus standards (typically ISO 10993 series)
- Electromagnetic compatibility (EMC) testing — these are electrically powered devices used in proximity to other medical equipment
- Labeling requirements that address the intended use, patient population, contraindications, and instructions for use with specificity
- Clinical or non-clinical data supporting any specific clinical claims about fracture healing outcomes
The full text of the special controls is codified in the new classification regulation. If you have a device in this product family, I would strongly recommend reading that regulatory text directly rather than relying on summaries — including this one.
What Changed for Devices Already on the Market
Here is where it gets practically important for manufacturers with devices currently marketed under product codes LOF or LPQ.
Devices that were already legally marketed as Class III under a PMA do not automatically lose that status. But the reclassification creates a new pathway for future devices and may affect post-market obligations for existing ones. Manufacturers should review whether:
- Their current device labeling and claims remain consistent with the newly codified classification regulation
- Any post-approval study requirements attached to an existing PMA are still in force (they generally remain until FDA formally modifies them)
- The reclassification opens an opportunity to transition to a 510(k)-based pathway for next-generation or modified versions of the device
For new market entrants, the path forward is clearer: submit a 510(k), identify an appropriate predicate, and satisfy the special controls. The predicate device pool has effectively expanded to include all previously cleared and approved devices in this category.
Practical Compliance Steps
If you are a manufacturer of non-invasive bone growth stimulators — or if you are planning to bring one to market — here is how I would approach the post-reclassification landscape.
Step 1: Read the final order and codified regulation in full. The Federal Register publication from April 16, 2026 is your primary source. The codified classification regulation contains the operative language for the special controls. Do not rely on press summaries.
Step 2: Assess your current product codes. If your device carries product code LOF or LPQ, confirm your current regulatory status — whether you hold a PMA, an IDE, or are in pre-submission discussions — and map how the reclassification affects your obligations.
Step 3: Evaluate your predicate landscape. For a 510(k), you need a predicate. With the reclassification, devices that were previously approved under PMA may now serve as predicates for substantial equivalence arguments. Work with your regulatory team to identify the strongest predicate and document the technological characteristics comparison carefully.
Step 4: Conduct a gap analysis against the special controls. Before you invest in a full 510(k) submission, map your existing test data, clinical data, and labeling against each of the newly established special controls. Identify where you have gaps and what testing or documentation is needed to close them.
Step 5: Update your design and development records. If you are in active development on a device in this category, your design inputs, verification and validation plan, and risk management file (ISO 14971) should all be updated to reflect the special controls as explicit design requirements. Under ISO 13485:2016 clause 7.3, the design input process should capture all regulatory and statutory requirements applicable to the device — and the new special controls qualify.
Step 6: Revisit labeling. Labeling is almost always a special control component. The codified regulation will specify what must appear in labeling. Review your current draft labeling — or your existing labeling if you are a current marketer — against those requirements.
Effective Dates and Deadlines
The final order was published April 16, 2026, in the Federal Register. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act) section 515(i), final reclassification orders are effective upon publication unless the order specifies otherwise.
What that means practically:
- Effective immediately (April 16, 2026): The reclassification is in effect. New devices in this category are now Class II and require a 510(k), not a PMA.
- Existing PMAs: Continue to govern currently marketed PMA-approved devices until FDA takes separate action or the manufacturer voluntarily transitions.
- Transitional submissions: Manufacturers who had PMAs in preparation or active review should consult with FDA — the reclassification may affect the appropriate submission type.
I have seen manufacturers caught off guard by mid-development reclassifications, and the consequences are rarely severe — but they do require a rapid reassessment of your submission strategy. If you are deep into a PMA for a device in this category, get on the phone with your FDA contact or request a pre-submission meeting sooner rather than later.
The Broader Pattern Worth Noticing
Reclassifications of this type — from Class III down to Class II with special controls — have become a reasonably common FDA tool as post-market evidence accumulates on device categories that were originally classified under the "default Class III" rule. Under the Safe Medical Devices Act of 1990, devices marketed before the 1976 Medical Device Amendments and not yet called up for PMA were effectively in Class III by default. As evidence matures and risk profiles become better understood, FDA exercises its authority under FD&C Act section 515(i) to reclassify.
Non-invasive bone growth stimulators have a long enough post-market history that FDA apparently found the evidence base sufficient to support a Class II designation with special controls. That is worth noting if you are in a similar device category that remains in Class III default status — the same reclassification pathway is available, and petitioning for it is a legitimate regulatory strategy.
According to the FDA's own device classification database, there are currently hundreds of device types still in default Class III postamendments status awaiting final classification calls. Each one is a potential reclassification candidate.
What This Means for Quality System Requirements
One thing that does not change with reclassification is your Quality Management System obligations. Whether your device is Class I, II, or III, if you are subject to FDA's Quality System Regulation (21 CFR Part 820) — or the harmonized Quality Management System Regulation (QMSR), which aligns 21 CFR Part 820 with ISO 13485:2016 — those requirements apply in full.
What does shift is the linkage between your QMS and your premarket submission. Under a 510(k) framework, your technical file and design history file need to demonstrate substantial equivalence and special controls compliance rather than the exhaustive clinical evidence package a PMA demands. That means your design control process (ISO 13485:2016 clause 7.3) and your risk management process (ISO 14971) are doing different evidentiary work. They need to be scoped accordingly.
If your team is navigating this reclassification while also preparing for a 510(k) submission or an ISO 13485 audit, understanding how FDA's special controls map to ISO 13485 design inputs is one of the more useful things you can work through early. The connection is tighter than most manufacturers initially expect.
A Note on What This Does Not Change
Reclassification to Class II does not mean these devices are low-risk in a clinical sense. Non-invasive bone growth stimulators are used in patients with non-union fractures, spinal fusion procedures, and other conditions where the stakes are real. The special controls exist precisely because FDA recognized that the residual risks require explicit mitigation.
In my experience, the companies that struggle most after a reclassification like this are the ones who treat it primarily as a pathway simplification — less paperwork, faster to market — without internalizing the fact that the special controls represent the floor of what is required to demonstrate safety and effectiveness, not a ceiling. Meeting special controls is necessary but not always sufficient, especially if you are making comparative clinical claims.
Summary
The FDA's April 2026 reclassification of non-invasive bone growth stimulators (LOF, LPQ) from Class III to Class II is a meaningful regulatory shift with practical implications for manufacturers, developers, and regulatory professionals in this device category. The 510(k) pathway is now the appropriate route for new devices. Special controls are the new compliance benchmark. Existing PMA holders retain their status but should assess their strategic posture. And the effective date is now.
If you want to work through how this reclassification affects your specific device program — whether that is a gap analysis against the special controls, a predicate search strategy, or a QMS update — Certify Consulting has supported more than 200 medical device clients through exactly these kinds of regulatory transitions. We can help you figure out where you stand and what to do next.
Last updated: 2026-04-20
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.